

# QBSAFE: A Randomized Trial of a Novel Intervention to Improve Care for People Living with Type 2 Diabetes



Kasia J Lipska, MD MHS<sup>1</sup>; Megan Branda, MS<sup>2</sup>; Anne Camp, MD<sup>3</sup>; Melissa Montosa, BS<sup>3</sup>; Rozalina McCoy, MD MS<sup>4</sup>; Victor Montori, BA<sup>5</sup>; Felipe Larios, MD<sup>5</sup> and Victor M Montori, MD MSc<sup>5</sup>.

Funded by NIDDK: R01DK129616  
ClinicalTrials.gov: NCT05553912

<sup>1</sup>Yale School of Medicine, New Haven, CT; <sup>2</sup>Mayo Clinic, Rochester, MN; <sup>3</sup>Fair Haven Community Health Center, New Haven, CT; <sup>4</sup>University of Maryland Institute for Health Computing, North Bethesda, MD; <sup>5</sup>Knowledge and Evaluation Research Unit, Rochester, MN

## Background

- People living with type 2 diabetes are expected to manage complex daily routines, self-monitor and respond to metabolic parameters, and coordinate access to ongoing care.
  - In busy or under-resourced clinical settings, clinicians may overlook the challenges of living with diabetes, despite their importance to patients' health and well-being.
  - Effective interventions are critically needed to align the encounter agenda with the needs of each patient, and to enable the co-creation of diabetes care plans that are sensible, desirable and feasible, i.e., care that fits.
  - The **QBSAFE agenda setting kit (ASK)** is a set of cards designed to help patients identify issues they would like to raise during the consultation pertaining to **Quality of Life, Burden of Treatment, Safety and Avoidance of Future Events**.
- ## Objective
- To estimate the effect of adding QBSAFE ASK to usual primary care on patient-reported and clinical outcomes of patients living with type 2 diabetes.

Figure 1. QBSAFE ASK tool.



## Methods

- **Study design:** Clinician-level cluster randomized trial.
- **Setting:** Federally qualified health center.
- **Participants:** 11 clinicians and 155 of their patients with type 2 diabetes and hemoglobin A1c >8% were randomly assigned to usual care either with or without the use of QBSAFE cards.
- **Primary outcomes:** Fit of care – measured by Illness Intrusiveness Ratings Scale (IIRS) at 6 months, and glycemic control – measured by hemoglobin A1c levels at 6 months.
- **Secondary outcomes:** Treatment burden – Treatment Burden Questionnaire (TBQ). Diabetes distress – Diabetes Distress Scale (DDS).
- **Other outcomes:** Quality of Life, patient and clinician satisfaction.
- A videographic analysis was performed to assess fidelity and the impact of QBSAFE on encounter discussions and care plans.

Figure 2. CONSORT diagram.




Figure 3. Study measures timeline.



## Results

Table 1: Characteristics of patient participants in the QBSAFE trial by study arm.

|                              | Study Arm         |               |
|------------------------------|-------------------|---------------|
|                              | Usual Care (N=69) | QBSAFE (N=74) |
| Age, Mean (SD)               | 53.8 (10.9)       | 58.4 (12.3)   |
| Sex, n (%)                   |                   |               |
| Female                       | 44 (64%)          | 43 (58%)      |
| Race, n (%)                  |                   |               |
| White                        | 19 (27%)          | 32 (43%)      |
| Black                        | 15 (22%)          | 13 (18%)      |
| Other                        | 29 (42%)          | 25 (34%)      |
| Unknown                      | 6 (9%)            | 4 (5%)        |
| Ethnicity, n (%)             |                   |               |
| Hispanic or Latino           | 53 (77%)          | 51 (69%)      |
| Primary Language, n (%)      |                   |               |
| English                      | 21 (30%)          | 34 (46%)      |
| Spanish                      | 48 (70%)          | 40 (54%)      |
| BMI, Mean (SD)               | 31.7 (5.12)       | 30.9 (5.63)   |
| Medical Insurance, n (%)     |                   |               |
| Commercial                   | 9 (13%)           | 11 (15%)      |
| Medicaid                     | 27 (39%)          | 26 (35%)      |
| Medicare                     | 13 (19%)          | 22 (30%)      |
| Self-Pay                     | 20 (29%)          | 15 (20%)      |
| Federal Poverty Level, n (%) |                   |               |
| 0-150%                       | 55 (90%)          | 61 (92%)      |
| >150%                        | 6 (10%)           | 5 (8%)        |
| Missing                      | 8                 | 8             |


Table 2: QBSAFE trial patient-reported and clinical outcomes at 6 months by study arm.

|                                        | Study Arm         |               | DID (95% CI)       | P-value           |
|----------------------------------------|-------------------|---------------|--------------------|-------------------|
|                                        | Usual Care (N=69) | QBSAFE (N=74) |                    |                   |
| Illness Intrusiveness Score: Mean (SD) | 37.1 (18.7)       | 32.1 (15.1)   | -3.9 (-10.4, 2.6)  | 0.24 <sup>1</sup> |
| Diabetes Distress Scale: Mean (SD)     | 2.3 (1.0)         | 2.0 (1.0)     | -0.09 (-0.4, 0.2)  | 0.49 <sup>1</sup> |
| < 2.0                                  | 24 (42%)          | 40 (61%)      |                    |                   |
| ≥2.0 to <3.0                           | 19 (33%)          | 14 (21%)      |                    |                   |
| ≥ 3.0                                  | 14 (25%)          | 12 (18%)      |                    |                   |
| Treatment Burden Questionnaire         | 46.8 (44.4)       | 41.2 (44.8)   | 1.01 (-16.6, 18.6) | 0.91 <sup>1</sup> |
| ≤59                                    | 40 (70%)          | 46 (70%)      |                    |                   |
| > 59                                   | 17 (30%)          | 20 (30%)      |                    |                   |
| HbA1c <sup>3</sup>                     | 9.1 (1.8)         | 8.8 (1.8)     | -0.2 (-0.9, 0.5)   | 0.59 <sup>1</sup> |
| HbA1c categories <sup>1</sup> , n (%)  |                   |               |                    | 0.47 <sup>2</sup> |
| <8.0                                   | 17 (26%)          | 26 (37%)      |                    |                   |
| 8.0 to <9.0                            | 14 (22%)          | 16 (22%)      |                    |                   |
| 9.0 to < 10.0                          | 14 (21%)          | 10 (14%)      |                    |                   |
| 10.0+                                  | 20 (31%)          | 19 (27%)      |                    |                   |

<sup>1</sup>Mixed generalized linear model adjusting for a fixed effect of arm and baseline score for the scale, and a random effect of clinician;  
<sup>2</sup>Rao-Scott Chi-Square p-value – accounting for clustering of clinician, no baseline scale adjustment;  
DID: Difference-in-Differences

- Encounter length did not differ between arms (22.2 vs. 22.1 minutes, p=0.95).
- QBSAFE encounters had significantly more discussions about burden of treatment, but not other domains (p=0.02).
- Patient satisfaction was overall high and did not vary between arms.

Figure 4. Clinician-reported satisfaction.



## Conclusions

- While QBSAFE ASK did not improve specific patient-reported or clinical outcomes in this trial, the cards offer a low-cost, feasible strategy to prompt conversations about treatment burden in primary care.
- Given the high levels of illness intrusiveness and distress among patients in this underserved setting, efforts to personalize and de-burden diabetes care remain a priority.
- Future interventions should focus on both enhancing conversations about treatment burden and equipping clinicians to meaningfully respond to patient's situations, particularly in high-need populations where the stakes for care fit are greatest.

## Research Partners

